Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Measurement of Current Substance Use in a Cohort of HIV-Infected Persons in Continuity HIV Care, 2007-2015.

Lesko CR, Keil AP, Moore RD, Chander G, Fojo AT, Lau B.

Am J Epidemiol. 2018 Sep 1;187(9):1970-1979. doi: 10.1093/aje/kwy092.

PMID:
29701832
2.

Revisiting the role of ABC transporters in multidrug-resistant cancer.

Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM.

Nat Rev Cancer. 2018 Jul;18(7):452-464. doi: 10.1038/s41568-018-0005-8. Review.

PMID:
29643473
3.

Multidrug-resistant tuberculosis in India: looking back, thinking ahead.

Fojo AT, Dowdy DW.

Lancet Public Health. 2017 Jan;2(1):e8-e9. doi: 10.1016/S2468-2667(16)30040-8. Epub 2016 Dec 19. No abstract available.

4.

Mathematical Modeling of "Chronic" Infectious Diseases: Unpacking the Black Box.

Fojo AT, Kendall EA, Kasaie P, Shrestha S, Louis TA, Dowdy DW.

Open Forum Infect Dis. 2017 Aug 14;4(4):ofx172. doi: 10.1093/ofid/ofx172. eCollection 2017 Fall.

5.

Current and future trends in tuberculosis incidence in New York City: a dynamic modelling analysis.

Fojo AT, Stennis NL, Azman AS, Kendall EA, Shrestha S, Ahuja SD, Dowdy DW.

Lancet Public Health. 2017 Jul;2(7):e323-e330. doi: 10.1016/S2468-2667(17)30119-6.

6.

A precision medicine approach for psychiatric disease based on repeated symptom scores.

Fojo AT, Musliner KL, Zandi PP, Zeger SL.

J Psychiatr Res. 2017 Dec;95:147-155. doi: 10.1016/j.jpsychires.2017.08.008. Epub 2017 Aug 11.

7.

Use of a 90-Minute Admission Window and Front-Fill System to Reduce Work Compression on a General Medicine Inpatient Teaching Service.

Choi Y, Kim D, Chong H, Mallow C, Bill J, Fojo AT, Blanchard M.

J Grad Med Educ. 2017 Apr;9(2):245-249. doi: 10.4300/JGME-D-16-00211.1.

8.

SDHB-related pheochromocytoma and paraganglioma penetrance and genotype-phenotype correlations.

Jochmanova I, Wolf KI, King KS, Nambuba J, Wesley R, Martucci V, Raygada M, Adams KT, Prodanov T, Fojo AT, Lazurova I, Pacak K.

J Cancer Res Clin Oncol. 2017 Aug;143(8):1421-1435. doi: 10.1007/s00432-017-2397-3. Epub 2017 Apr 3.

9.

Functional Imaging Signature of Patients Presenting with Polycythemia/Paraganglioma Syndromes.

Janssen I, Chen CC, Zhuang Z, Millo CM, Wolf KI, Ling A, Lin FI, Adams KT, Herscovitch P, Feelders RA, Fojo AT, Taieb D, Kebebew E, Pacak K.

J Nucl Med. 2017 Aug;58(8):1236-1242. doi: 10.2967/jnumed.116.187690. Epub 2017 Mar 23.

10.

Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysis.

Kendall EA, Fojo AT, Dowdy DW.

Lancet Respir Med. 2017 Mar;5(3):191-199. doi: 10.1016/S2213-2600(16)30423-4. Epub 2016 Dec 16. Erratum in: Lancet Respir Med. 2017 Feb;5(2):e13.

11.

Inhibiting mitochondrial respiration prevents cancer in a mouse model of Li-Fraumeni syndrome.

Wang PY, Li J, Walcott FL, Kang JG, Starost MF, Talagala SL, Zhuang J, Park JH, Huffstutler RD, Bryla CM, Mai PL, Pollak M, Annunziata CM, Savage SA, Fojo AT, Hwang PM.

J Clin Invest. 2017 Jan 3;127(1):132-136. doi: 10.1172/JCI88668. Epub 2016 Nov 21.

12.

PET/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma.

Janssen I, Chen CC, Millo CM, Ling A, Taieb D, Lin FI, Adams KT, Wolf KI, Herscovitch P, Fojo AT, Buchmann I, Kebebew E, Pacak K.

Eur J Nucl Med Mol Imaging. 2016 Sep;43(10):1784-91. doi: 10.1007/s00259-016-3357-x. Epub 2016 Mar 21.

PMID:
26996779
13.

68Ga-DOTATATE PET/CT in the Localization of Head and Neck Paragangliomas Compared with Other Functional Imaging Modalities and CT/MRI.

Janssen I, Chen CC, Taieb D, Patronas NJ, Millo CM, Adams KT, Nambuba J, Herscovitch P, Sadowski SM, Fojo AT, Buchmann I, Kebebew E, Pacak K.

J Nucl Med. 2016 Feb;57(2):186-91. doi: 10.2967/jnumed.115.161018. Epub 2015 Nov 12.

14.

High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses.

Mossoba ME, Halverson DC, Kurlander R, Schuver BB, Carpenter A, Hansen B, Steinberg SM, Ali SA, Tageja N, Hakim FT, Gea-Banacloche J, Sportes C, Hardy NM, Hickstein DD, Pavletic SZ, Khuu H, Sabatini M, Stroncek D, Levine BL, June CH, Mariotti J, Rixe O, Fojo AT, Bishop MR, Gress RE, Fowler DH.

Clin Cancer Res. 2015 Oct 1;21(19):4312-20. doi: 10.1158/1078-0432.CCR-15-0340. Epub 2015 Jun 12.

15.

Breast implant-associated anaplastic large cell lymphoma in a patient with Li-Fraumeni syndrome.

Lee YS, Filie A, Arthur D, Fojo AT, Jaffe ES.

Histopathology. 2015 Dec;67(6):925-7. doi: 10.1111/his.12737. Epub 2015 Jun 18. No abstract available.

16.

Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma.

Janssen I, Blanchet EM, Adams K, Chen CC, Millo CM, Herscovitch P, Taieb D, Kebebew E, Lehnert H, Fojo AT, Pacak K.

Clin Cancer Res. 2015 Sep 1;21(17):3888-95. doi: 10.1158/1078-0432.CCR-14-2751. Epub 2015 Apr 14.

17.

Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins.

Poruchynsky MS, Komlodi-Pasztor E, Trostel S, Wilkerson J, Regairaz M, Pommier Y, Zhang X, Kumar Maity T, Robey R, Burotto M, Sackett D, Guha U, Fojo AT.

Proc Natl Acad Sci U S A. 2015 Feb 3;112(5):1571-6. doi: 10.1073/pnas.1416418112. Epub 2015 Jan 20.

18.

Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer.

Conlon KC, Lugli E, Welles HC, Rosenberg SA, Fojo AT, Morris JC, Fleisher TA, Dubois SP, Perera LP, Stewart DM, Goldman CK, Bryant BR, Decker JM, Chen J, Worthy TA, Figg WD Sr, Peer CJ, Sneller MC, Lane HC, Yovandich JL, Creekmore SP, Roederer M, Waldmann TA.

J Clin Oncol. 2015 Jan 1;33(1):74-82. doi: 10.1200/JCO.2014.57.3329. Epub 2014 Nov 17.

19.

External beam radiation therapy in treatment of malignant pheochromocytoma and paraganglioma.

Vogel J, Atanacio AS, Prodanov T, Turkbey BI, Adams K, Martucci V, Camphausen K, Fojo AT, Pacak K, Kaushal A.

Front Oncol. 2014 Jun 27;4:166. doi: 10.3389/fonc.2014.00166. eCollection 2014.

20.

Clinical trial results: a clinical trial bazaar!

Fojo AT, Bates SE.

Oncologist. 2014 Apr;19(4):313-4. doi: 10.1634/theoncologist.2014-0091. Epub 2014 Mar 25. No abstract available.

21.

Acetyl-L-carnitine and prevention of chemotherapy-induced peripheral neuropathy: can anything work?

Burotto M, Fojo AT.

Oncologist. 2013;18(11):1151-2. doi: 10.1634/theoncologist.2013-0385. No abstract available.

22.

Clinical trial results: Sharing results, speeding discoveries.

Fojo AT, Bates SE, Chabner BA.

Oncologist. 2013;18(7):779. doi: 10.1634/theoncologist.2013-0247. No abstract available.

23.

Sunitinib does not accelerate tumor growth in patients with metastatic renal cell carcinoma.

Blagoev KB, Wilkerson J, Stein WD, Motzer RJ, Bates SE, Fojo AT.

Cell Rep. 2013 Feb 21;3(2):277-81. doi: 10.1016/j.celrep.2013.01.015. Epub 2013 Feb 7.

24.

RECIST: no longer the sharpest tool in the oncology clinical trials toolbox--reply to point.

Fojo AT, Noonan A.

Cancer Res. 2012 Oct 15;72(20):5150. doi: 10.1158/0008-5472.CAN-12-1989. Epub 2012 Sep 4. No abstract available.

25.

Why RECIST works and why it should stay--counterpoint.

Fojo AT, Noonan A.

Cancer Res. 2012 Oct 15;72(20):5151-7; discussion 5158. doi: 10.1158/0008-5472.CAN-12-0733. Epub 2012 Sep 4.

26.

Interleukin-13 receptor alpha2 is a novel therapeutic target for human adrenocortical carcinoma.

Jain M, Zhang L, He M, Patterson EE, Nilubol N, Fojo AT, Joshi B, Puri R, Kebebew E.

Cancer. 2012 Nov 15;118(22):5698-708. doi: 10.1002/cncr.27629. Epub 2012 May 8.

27.

Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies.

Amiri-Kordestani L, Basseville A, Kurdziel K, Fojo AT, Bates SE.

Drug Resist Updat. 2012 Feb-Apr;15(1-2):50-61. doi: 10.1016/j.drup.2012.02.002. Epub 2012 Mar 29. Review.

28.

Analyzing the pivotal trial that compared sunitinib and IFN-α in renal cell carcinoma, using a method that assesses tumor regression and growth.

Stein WD, Wilkerson J, Kim ST, Huang X, Motzer RJ, Fojo AT, Bates SE.

Clin Cancer Res. 2012 Apr 15;18(8):2374-81. doi: 10.1158/1078-0432.CCR-11-2275. Epub 2012 Feb 17.

29.

The Role of Wild-Type p53 in Cisplatin-Induced Chk2 Phosphorylation and the Inhibition of Platinum Resistance with a Chk2 Inhibitor.

Liang X, Guo Y, Figg WD, Fojo AT, Mueller MD, Yu JJ.

Chemother Res Pract. 2011;2011:715469. doi: 10.1155/2011/715469. Epub 2010 Dec 1.

30.

Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale.

Komlodi-Pasztor E, Sackett DL, Fojo AT.

Clin Cancer Res. 2012 Jan 1;18(1):51-63. doi: 10.1158/1078-0432.CCR-11-0999. Review.

31.

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.

Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, Jaffe ES, Ling A, Turner M, Peer CJ, Figg WD, Steinberg SM, Smith S, Joske D, Lewis I, Hutchins L, Craig M, Fojo AT, Wright JJ, Bates SE.

Blood. 2011 Jun 2;117(22):5827-34. doi: 10.1182/blood-2010-10-312603. Epub 2011 Feb 25.

32.

Increased uptake of [¹²³I]meta-iodobenzylguanidine, [¹⁸F]fluorodopamine, and [³H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors.

Martiniova L, Perera SM, Brouwers FM, Alesci S, Abu-Asab M, Marvelle AF, Kiesewetter DO, Thomasson D, Morris JC, Kvetnansky R, Tischler AS, Reynolds JC, Fojo AT, Pacak K.

Endocr Relat Cancer. 2011 Jan 13;18(1):143-57. doi: 10.1677/ERC-10-0090. Print 2011 Feb.

33.

Radiofrequency ablation of metastatic pheochromocytoma.

Venkatesan AM, Locklin J, Lai EW, Adams KT, Fojo AT, Pacak K, Wood BJ.

J Vasc Interv Radiol. 2009 Nov;20(11):1483-90. doi: 10.1016/j.jvir.2009.07.031.

34.

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.

Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH, Zain J, Prince HM, Leonard JP, Geskin LJ, Reeder C, Joske D, Figg WD, Gardner ER, Steinberg SM, Jaffe ES, Stetler-Stevenson M, Lade S, Fojo AT, Bates SE.

J Clin Oncol. 2009 Nov 10;27(32):5410-7. doi: 10.1200/JCO.2008.21.6150. Epub 2009 Oct 13.

35.

Mediastinal paragangliomas: association with mutations in the succinate dehydrogenase genes and aggressive behavior.

Ghayee HK, Havekes B, Corssmit EP, Eisenhofer G, Hammes SR, Ahmad Z, Tessnow A, Lazúrová I, Adams KT, Fojo AT, Pacak K, Auchus RJ.

Endocr Relat Cancer. 2009 Mar;16(1):291-9. doi: 10.1677/ERC-08-0214. Epub 2008 Dec 15.

36.

Ex vivo rapamycin generates apoptosis-resistant donor Th2 cells that persist in vivo and prevent hemopoietic stem cell graft rejection.

Mariotti J, Foley J, Jung U, Borenstein T, Kantardzic N, Han S, Hanson JT, Wong E, Buxhoeveden N, Trepel JB, Fojo AT, Telford W, Fowler DH.

J Immunol. 2008 Jan 1;180(1):89-105.

37.

Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR).

Fojo AT, Menefee M.

Semin Oncol. 2005 Dec;32(6 Suppl 7):S3-8. Review.

PMID:
16360716
38.

Introduction: chemotherapies in the treatment of breast cancer.

Fojo AT.

Semin Oncol. 2005 Dec;32(6 Suppl 7):S1-2. Review. No abstract available.

PMID:
16360715
39.

Development of gene ontology tool for biological interpretation of genomic and proteomic data.

Feng W, Wang G, Zeeberg BR, Guo K, Fojo AT, Kane DW, Reinhold WC, Lababidi S, Weinstein JN, Wang MD.

AMIA Annu Symp Proc. 2003:839.

40.

GoMiner: a resource for biological interpretation of genomic and proteomic data.

Zeeberg BR, Feng W, Wang G, Wang MD, Fojo AT, Sunshine M, Narasimhan S, Kane DW, Reinhold WC, Lababidi S, Bussey KJ, Riss J, Barrett JC, Weinstein JN.

Genome Biol. 2003;4(4):R28. Epub 2003 Mar 25.

41.

Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.

Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP, Bates SE.

Clin Cancer Res. 2002 Mar;8(3):718-28.

42.

Expression of the multidrug resistance-associated protein gene in refractory lymphoma: quantitation by a validated polymerase chain reaction assay.

Zhan Z, Sandor VA, Gamelin E, Regis J, Dickstein B, Wilson W, Fojo AT, Bates SE.

Blood. 1997 May 15;89(10):3795-800.

43.

Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance.

Wang LF, Ting CY, Lo CK, Su JS, Mickley LA, Fojo AT, Whang-Peng J, Hwang J.

Cancer Res. 1997 Apr 15;57(8):1516-22.

44.

Initial pharmacokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist.

Lush RM, Meadows B, Fojo AT, Kalafsky G, Smith HT, Bates S, Figg WD.

J Clin Pharmacol. 1997 Feb;37(2):123-8.

PMID:
9055138
45.

Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations.

Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, Andreeff M, Bates SE, Berard CW, Boyett JM, Brophy NA, Broxterman HJ, Chan HS, Dalton WS, Dietel M, Fojo AT, Gascoyne RD, Head D, Houghton PJ, Srivastava DK, Lehnert M, Leith CP, Paietta E, Pavelic ZP, Weinstein R.

Cancer Res. 1996 Jul 1;56(13):3010-20. Review.

46.

Clinical Reversal of Multidrug Resistance.

Bates SE, Wilson WH, Fojo AT, Alvarez M, Zhan Z, Regis J, Robey R, Hose C, Monks A, Kang YK, Chabner B.

Oncologist. 1996;1(4):269-275.

47.

Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.

Asano T, An T, Zwelling LA, Takano H, Fojo AT, Kleinerman ES.

Oncol Res. 1996;8(3):101-10.

PMID:
8823806
48.

Clinical reversal of multidrug resistance.

Bates SE, Wilson WH, Fojo AT, Alvarez M, Zhan Z, Regis J, Robey R, Hose C, Monks A, Kang YK, Chabner B.

Stem Cells. 1996 Jan;14(1):56-63. Review.

49.

Expression of a 95 kDa membrane protein is associated with low daunorubicin accumulation in leukaemic blast cells.

Doyle LA, Ross DD, Sridhara R, Fojo AT, Kaufmann SH, Lee EJ, Schiffer CA.

Br J Cancer. 1995 Jan;71(1):52-8.

50.

Molecular targets in the National Cancer Institute drug screen.

Bates SE, Fojo AT, Weinstein JN, Myers TG, Alvarez M, Pauli KD, Chabner BA.

J Cancer Res Clin Oncol. 1995;121(9-10):495-500. Review. No abstract available.

PMID:
7559726

Supplemental Content

Support Center